Tetra Bio Pharma Inc. (“Tetra” or the “Company”) (TBP.V) (TBPMF) a leader in cannabinoid-derived drug discovery and development, is pleased to announce the appointment of Sylvain Chrétien as President of Tetra Bio-Pharma Inc. Mr. Chrétien will report directly to Guy Chamberland, CEO of Tetra.
Mr. Chamberland was instrumental in selecting the Company’s first President so that he could devote more time to the regulatory strategies and drug development of Caumz, Qixleef and HCC011. As President, Mr. Chrétien will be responsible for investor relations and preparing Tetra for the commercialization of Caumz and Qixleef. The CEO and President will continue to promote Tetra and work with the CFO on future financings.
“I am thrilled to welcome Sylvain to our senior executive team at this exciting time. He brings with him decades of experience and a deep understanding of the biopharmaceutical industry, along with a proven track record of successful leadership in managing growth,” stated Dr. Guy Chamberland, CEO and CRO of Tetra Bio-Pharma Inc. “We look forward to his contributions as we continue to deliver on our strategy and transform to a fully integrated biopharmaceutical company.”
During his 31-year career, Mr. Chrétien has served in senior leadership roles at several well-respected and innovative companies. In his most recent position, Mr. Chrétien served as both the Canadian President and Board Member for Medexus Pharmaceutical Inc. Prior to that, Mr. Chrétien founded Pediapharm Inc., a Medexus predecessor entity, and loyally served as its President and Chief Executive Officer from 2008 until 2018. Mr. Chrétien successfully guided Pediapharm from its infancy into a solidly flourishing Company demonstrating his commercial development, operational, manufacturing, and financial leadership skills. As a result of his astute leadership and guidance, Pediapharm developed into one of Canada’s leading pediatric specialty pharma companies. In late 2018, Mr. Chretien successfully completed a transformative transaction for Pediapharm resulting in the merger of 3 entities: Pediapharm, Medexus and Medac U.S., creating Medexus Pharmaceutical Inc.; a North American specialty pharma company.
Mr. Sylvain Chrétien, stated “I am honored to join Dr. Chamberland and the entire team of Tetra as they work to develop QIXEEF and CAUMZ for patients with advanced cancer pain. Helping businesses grow into fully integrated biopharmaceutical companies has been a cornerstone of my career and I’m thrilled to join the Tetra team as it moves forward in its mission in developing its cannabinoid drug derived therapies.”
About Tetra Bio-Pharma
Tetra Bio-Pharma (TBP.V) (TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including this trial, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For further information, please contact Tetra Bio-Pharma Inc.
LifeSci Advisors LLC
Media Contact US:
LifeSci Public Relations
Media Contact Canada:
Energi PR Inc.
514-288-8500 ext. 226